Pharmacokinetics of the H2‐ receptor antagonist ranitidine in man.

JJ McNeil, GW Mihaly, A. Anderson, AW Marshall, RA Smallwood, WJ Louis

Research output: Contribution to journalArticleResearchpeer-review

61 Citations (Scopus)

Abstract

1 Ranitidine pharmacokinetics were studied in six healthy volunteers. Following an overnight fast, doses of 20 mg intravenously 20, 40 and 100 mg orally and 100 mg orally with a standard meal, were administered to each subject on separate occasions. 2 Following intravenous administration there was a bioexponential decline in plasma levels from 576 +/‐ 56 ng/ml at 4 min to 10 +/‐ 2 ng/ml at 8 h. The distribution half‐life (T 1/2 alpha) was 6.1 +/‐ 0.9 min, elimination half‐life (T 1/2 beta) was 1.9 +/‐ 0.1 h, the volume of distribution (Vd beta) was 115 +/‐ 7 l and systemic plasma clearance (Cltp) was 709 +/‐ 62 ml/min. 3 Following 20 mg oral doses, peak levels were reached at 1.6 +/‐ 0.2 h and the systemic availability was 88 +/‐ 10%. Elimination half‐life (T 1/2 beta) was unaffected by dose and the area under the curve increased linearly with dose and was unaffected by food. 4 Renal excretion (24 h) of unmetabolized ranitidine accounted for 50‐70% of the dose with a further 1‐3% appearing as desmethyl ranitidine. 1981 The British Pharmacological Society

Original languageEnglish
Pages (from-to)411-415
Number of pages5
JournalBritish Journal of Clinical Pharmacology
Volume12
Issue number3
DOIs
Publication statusPublished - 1 Jan 1981

Cite this